Ask AI
OPTI-AML
OPTI-AML: Phase II Trial of 28-Day vs 14-Day Venetoclax and Azacitidine for 2 Cycles in Patients Aged ≥60 Years with Newly Diagnosed Genomically Agnostic AML

Released: July 01, 2026

Activity

Progress
1
Course Completed
Activity Information

Released: July 01, 2026